Early-stage cancers release only trace amounts of tumor-derived signals into the bloodstream. Current liquid biopsy approaches rely primarily on detecting sparse cfDNA fragments, requiring ultra-deep sequencing, complex analytics, and high-cost testing to achieve sufficient sensitivity.